Business Context and Reporting Period
This Form 8-K Current Report from Anika Therapeutics, Inc. covers the Annual Meeting of Stockholders held on June 18, 2026. The filing details the results of shareholder votes on director elections, auditor ratification, executive compensation, and amendments to equity incentive plans.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Equity Plan Amendments: Stockholders approved increasing the share reserve for the 2017 Omnibus Incentive Plan by 350,000 shares (to 6,110,000 total) and the 2021 Employee Stock Purchase Plan (ESPP) by 200,000 shares (to 400,000 total).
- Director Elections: Gary P. Fischetti, John B. Henneman, III, and Stephen D. Griffin were elected as Class III directors.
- Auditor Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results and Management Commentary
The Annual Meeting saw 84.14% of voting power represented (11,195,667 shares present out of 13,305,624 entitled to vote). Key voting outcomes include:
- Proposal 1 (Directors): All three nominees received majority support, though John B. Henneman, III received a higher "Against" vote count (536,988) compared to the other nominees.
- Proposal 2 (Auditor): Overwhelmingly approved with 11,136,590 "For" votes.
- Proposal 3 (Say-on-Pay): Approved on a non-binding advisory basis with 8,268,676 "For" votes, though 1,093,946 votes were cast "Against."
- Proposal 4 (Omnibus Plan): Approved with 8,013,994 "For" votes.
- Proposal 5 (ESPP): Approved with 9,110,892 "For" votes.
There was no solicitation in opposition to the Board's proposals.
Investor Verification Checklist
- Verify the full text of the Seventh Amended and Restated 2017 Omnibus Incentive Plan (Exhibit 10.1) to understand specific terms of the new 350,000 share increase.
- Review the 2021 Employee Stock Purchase Plan amendment (Exhibit 10.2) for details on the 200,000 share increase.
- Examine the Proxy Statement (filed April 28, 2026, with supplements) for the Compensation Discussion and Analysis referenced in the Say-on-Pay vote.
- Monitor future filings for the 2026 Annual Report (10-K) to obtain the actual financial performance metrics absent from this 8-K.